Edwards Lifesciences (EW) Free Cash Flow (2009 - 2026)

Edwards Lifesciences' Free Cash Flow history runs 18 years deep, the most recent figure standing at -$21.1 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 109.4% year-over-year to -$21.1 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 72.09% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 360.5% from the prior year.
• Free Cash Flow eased to -$21.1 million in Q1 2026 per EW's latest filing, from $353.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $516.2 million in Q3 2025 and bottomed at -$177.3 million in Q4 2024.
• The 5-year median for Free Cash Flow is $240.9 million (2025), against an average of $189.4 million.
• Biggest YoY gain for Free Cash Flow was 2100.7% in 2024; the steepest drop was 467.08% in 2024.
• Year by year, Free Cash Flow stood at $213.9 million in 2022, then tumbled by 77.42% to $48.3 million in 2023, then sank by 467.08% to -$177.3 million in 2024, then jumped by 299.38% to $353.5 million in 2025, then tumbled by 105.97% to -$21.1 million in 2026.
• Per Business Quant, the three latest EW Free Cash Flow figures stand at -$21.1 million (Q1 2026), $353.5 million (Q4 2025), and $516.2 million (Q3 2025).